glp 1 agonist cardiovascular outcomes Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Human, exendin-based GLP-1 receptor agonists

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

Now it has been shown that limited experimental data can be used to train sophisticated machine learning models to accurately predict the activity of previously uncharacterized peptide ligand variants.

Retatrutide targets GLP-1, GIP & glucagon receptors

What if I do not qualify for full-dose semaglutide

Check with your health insurance or your employer health program to see if it is covered

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)